BACKGROUND: Antibodies to complexes of heparin and platelet factor 4 (PF4) are capable of causing heparin-induced thrombocytopenia (HIT). Recent evidence suggests that anti-PF4/heparin antibodies may be prothrombogenic even in the absence of thrombocytopenia and clinically-recognized HIT. OBJECTIVES: To determine if induction of anti-PF4/heparin antibodies is an independent risk factor for early saphenous vein graft (SVG) occlusion or adverse clinical outcome after coronary artery bypass graft (CABG) surgery. PATIENTS/ METHODS: Anti-PF4/heparin antibody titers were measured in 368 patients prior to and then 4 days, 6 weeks and 6 months after CABG surgery. Serotonin release assay (SRA) and antibody isotype analysis were also performed on 6-week samples. SVG patency was determined in 297 patients 6 months after surgery by multidetector computed tomography coronary angiography. RESULTS: Six weeks after surgery, 52% of patients were anti-PF4/heparin seropositive and 9% were SRA positive. Six months after surgery, neither the percentage of occluded SVG (19% vs. 20%, P = NS), the percentage of patients with an occluded SVG (33% vs. 33%, P = NS) nor the incidence of adverse clinical events (21% vs. 24%, P = NS) differed between seropositive and seronegative groups. Neither IgG isotype nor SRA positivity was additionally predictive of SVG occlusion or adverse clinical outcome. CONCLUSION: Induction of anti-PF4/heparin antibodies, even those capable of heparin-dependent platelet activation, is not independently associated with early SVG occlusion or adverse clinical outcomes after CABG surgery.
BACKGROUND: Antibodies to complexes of heparin and platelet factor 4 (PF4) are capable of causing heparin-induced thrombocytopenia (HIT). Recent evidence suggests that anti-PF4/heparin antibodies may be prothrombogenic even in the absence of thrombocytopenia and clinically-recognized HIT. OBJECTIVES: To determine if induction of anti-PF4/heparin antibodies is an independent risk factor for early saphenous vein graft (SVG) occlusion or adverse clinical outcome after coronary artery bypass graft (CABG) surgery. PATIENTS/ METHODS: Anti-PF4/heparin antibody titers were measured in 368 patients prior to and then 4 days, 6 weeks and 6 months after CABG surgery. Serotonin release assay (SRA) and antibody isotype analysis were also performed on 6-week samples. SVG patency was determined in 297 patients 6 months after surgery by multidetector computed tomography coronary angiography. RESULTS: Six weeks after surgery, 52% of patients were anti-PF4/heparin seropositive and 9% were SRA positive. Six months after surgery, neither the percentage of occluded SVG (19% vs. 20%, P = NS), the percentage of patients with an occluded SVG (33% vs. 33%, P = NS) nor the incidence of adverse clinical events (21% vs. 24%, P = NS) differed between seropositive and seronegative groups. Neither IgG isotype nor SRA positivity was additionally predictive of SVG occlusion or adverse clinical outcome. CONCLUSION: Induction of anti-PF4/heparin antibodies, even those capable of heparin-dependent platelet activation, is not independently associated with early SVG occlusion or adverse clinical outcomes after CABG surgery.
Authors: Tyler J Gluckman; Jodi B Segal; Natalie L Fredde; Kenneth E Saland; Jayesh T Jani; Jeanine M Walenga; M Margaret Prechel; Kathleen M Citro; David A Zidar; Emily Fox; Steven P Schulman; Thomas S Kickler; Jeffrey J Rade Journal: Am J Cardiol Date: 2005-03-15 Impact factor: 2.778
Authors: Brendan M Everett; Robert Yeh; Shi Yin Foo; David Criss; Elizabeth M Van Cott; Michael Laposata; Edwin G Avery; William D Hoffman; Jennifer Walker; David Torchiana; Ik-Kyung Jang Journal: Ann Thorac Surg Date: 2007-02 Impact factor: 4.330
Authors: Elliott Bennett-Guerrero; Thomas F Slaughter; William D White; Ian J Welsby; Charles S Greenberg; Habib El-Moalem; Thomas L Ortel Journal: J Thorac Cardiovasc Surg Date: 2005-12 Impact factor: 5.209
Authors: John H Alexander; Gail Hafley; Robert A Harrington; Eric D Peterson; T Bruce Ferguson; Todd J Lorenz; Abhinav Goyal; Michael Gibson; Michael J Mack; Daniel Gennevois; Robert M Califf; Nicholas T Kouchoukos Journal: JAMA Date: 2005-11-16 Impact factor: 56.272
Authors: Tyler J Gluckman; Rhondalyn C McLean; Steven P Schulman; Thomas S Kickler; Edward P Shapiro; John V Conte; Kathleen W McNicholas; Jodi B Segal; Jeffrey J Rade Journal: J Am Coll Cardiol Date: 2011-03-01 Impact factor: 24.094
Authors: R C McLean; S M Nazarian; T J Gluckman; S P Schulman; D R Thiemann; E P Shapiro; J V Conte; J B Thompson; I Shafique; K W McNicholas; T C Villines; K M Laws; J J Rade Journal: J Cardiovasc Surg (Torino) Date: 2011-12 Impact factor: 1.888
Authors: Navin K Kapur; Ce Bian; Edward Lin; Clayton B Deming; Jason L Sperry; Baranda S Hansen; Nikolaos Kakouros; Jeffrey J Rade Journal: J Vasc Surg Date: 2011-07-31 Impact factor: 4.268
Authors: I J Welsby; E F Krakow; J A Heit; E C Williams; G M Arepally; S Bar-Yosef; D F Kong; S Martinelli; I Dhakal; W W Liu; J Krischer; T L Ortel Journal: J Thromb Haemost Date: 2016-11-30 Impact factor: 5.824
Authors: Adam Cuker; Lubica Rauova; Douglas Bolgiano; William H Matthai; Mortimer Poncz; Barbara A Konkle Journal: Thromb Haemost Date: 2014-01-30 Impact factor: 5.249
Authors: Susanna M Nazarian; Jason B Thompson; Tyler J Gluckman; Katherine Laws; Jayesh T Jani; Thomas S Kickler; Jeffrey J Rade Journal: Thromb Res Date: 2009-06-05 Impact factor: 3.944